Analyze Diet
BMC medicine2025; 23(1); 439; doi: 10.1186/s12916-025-04231-7

Cryopreserved equine umbilical cord tissue allograft characterization and biocompatibility in vivo in musculoskeletal tissues: a controlled study.

Abstract: The use of micro-particulate allografts is rising, but knowledge about the protein characterization and biocompatibility of umbilical cord-derived allografts (UC) in vivo is limited. Methods: Proteomic analyses using mass spectrometry (MS) determined equine UC protein relative quantification and functions using total spectral counts (TSC). UC cytokines were quantified by enzyme-linked immunosorbent assay (ELISA). Three in vivo studies assessed recipient clinical and tissue biocompatibility in joints and ligaments. Results: Proteomics revealed 2645 annotated TSCs. Proteins of > 89 TSC were considered abundant and were present in all donors. Proteins within the same donor had a 4.7% mean variation. Inflammatory cytokines were low in UC. In vivo, the prospective randomized, masked, controlled study in carpal joints and ligaments of clinically normal horses had median scores of 0 (none) for lameness and pain for 42 days. Synovial fluid showed a transient transudative synovitis after UC injection that was greater than baseline and control and returned to normal after day 5 (P < 0.001). Synovial fluid inflammatory cytokines were low; however, the anti-inflammatory cytokines Il-1ra, Il-10, and Il-1ra/Il-1 ratio were greater after UC injection than at baseline and control (P < 0.001). Blood hematology, chemistries, and serum amyloid A did not reveal systemic effects. The in vivo study of osteoarthritis and desmitis/tendonitis improved in lameness and pain over a 28-day study and had parallel synovial fluid results to the normal horse study, also without adverse events. The in vivo pathologic study evaluated joint and ligament tissues 2 and 5 days after injection and corresponding lymph nodes for evidence of the allograft or inflammation. The synovial membrane, articular cartilage, and lymph nodes were histologically normal, except for mild inflammation in the injection tracts. Conclusions: Well-defined proteins were consistently present in different donors and within batches. Proteins included fibrillar and glycan proteins with a variety of roles and regulatory functions in the connective tissue matrix. The rise in Il-1ra and high Il-1ra/Il-1 ratio after UC injection could block the catabolic effect of Il-1. No adverse events were observed. Within the limits of this study, UC was safe for injection into joints and ligaments in clinically normal horses.
Publication Date: 2025-07-23 PubMed ID: 40702469PubMed Central: PMC12288288DOI: 10.1186/s12916-025-04231-7Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research is about testing the biocompatibility of umbilical cord-derived allografts (UCs) in equine (horse) musculoskeletal tissues. The study reveals that these allografts have a consistent protein composition and can safely be injected into the joints and ligaments without causing adverse effects.

Proteomic Analysis and Cytokine Assessment

  • The research used mass spectrometry, a technique for measuring the mass and concentration of ions, to quantify and understand the function of proteins in the equine umbilical cord (UC).
  • The researchers identified 2645 annotated total spectral counts (TSCs), with proteins having more than 89 TSCs being considered abundant and consistently present across all samples.
  • There was a mean variation of only 4.7% among proteins within a single donor, indicating a high level of consistency.
  • Inflammation-causing cytokines were found to be low in the UC. These cytokines were quantified using enzyme-linked immunosorbent assay (ELISA), a common lab technique to measure antigens in a sample.

In Vivo Biocompatibility Studies

  • Three separate studies were conducted to assess the biocompatibility of UCs when injected into the joints and ligaments of horses.
  • The first, a randomized controlled study, involved injecting the UCs into the carpal (wrist) joints and ligaments of clinically normal horses. These horses displayed no signs of lameness or pain for the duration of the 42-day study.
  • Synovial fluid, a lubricating fluid in joints that reduces friction between cartilage, exhibited a brief increase in inflammation following the injection. However, this returned to normal after five days.
  • The researchers found low levels of inflammatory cytokines in the synovial fluid, but they observed a higher count of specific anti-inflammatory cytokines (Il-1ra and Il-10) after UC injection, suggesting that UC might have an inflammation-dampening effect.

Additional In Vivo Studies

  • The second study focused on horses with osteoarthritis and tendonitis. When treated with UC, these horses demonstrated improved conditions over a 28-day period, without any adverse side effects.
  • The final study investigated the tissues and corresponding lymph nodes for inflammation or other impacts of the UCs two and five days post-injection. The researchers found the synovial membranes, articular cartilage, and lymph nodes to be largely normal, except for mild inflammation.

Conclusions and Implications

  • The study concludes that UC allografts have a consistent protein composition, which includes fibrillar and glycan proteins that play various important roles in the connective tissue matrix.
  • The rise in specific anti-inflammatory cytokines after UC injection suggests that UCs might help to block inflammation, making them potentially useful for treatment in a variety of inflammatory conditions.
  • No adverse effects were observed in any of the in vivo studies, indicating that UCs are safe for injection into horse joints and ligaments.

Cite This Article

APA
Bertone AL, Reinemeyer C, Tsaprailis G, Ragland D, Leise B. (2025). Cryopreserved equine umbilical cord tissue allograft characterization and biocompatibility in vivo in musculoskeletal tissues: a controlled study. BMC Med, 23(1), 439. https://doi.org/10.1186/s12916-025-04231-7

Publication

ISSN: 1741-7015
NlmUniqueID: 101190723
Country: England
Language: English
Volume: 23
Issue: 1
Pages: 439
PII: 439

Researcher Affiliations

Bertone, Alicia L
  • Department of Veterinary Clinical Sciences (Emeritus), The Ohio State University, 1900 Coffey Rd, Columbus, OH, 43210, USA. Alicia.bertone@gmail.com.
Reinemeyer, Craig
  • East Tennessee Clinical Research, Inc, 80 Copper Ridge Farm Rd, Rockwood, TN, 37854, USA.
Tsaprailis, George
  • The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology; Mass Spectrometry and Proteomics Core Facility, University of Florida, 130 Scripps Way 1B2, Jupiter, FL, 33458, USA.
Ragland, Daniel
  • Veterinary Reference Laboratories, 7540 Louis Pasteur Drive, Suite 200, San Antonio, TX, 78229, USA.
Leise, Britta
  • Department of Veterinary Clinical Sciences, Louisiana State University, Dr Skip Bertman, Baton Rouge, LA, USA.

MeSH Terms

  • Animals
  • Horses
  • Allografts
  • Umbilical Cord / transplantation
  • Cryopreservation
  • Cytokines / analysis
  • Cytokines / metabolism
  • Prospective Studies
  • Female
  • Proteomics
  • Synovial Fluid
  • Male

Conflict of Interest Statement

Declarations. Ethics approval and consent to participate: Animal studies were performed in accordance with and by approval of Institutional Animal Care and Use Committees (ETCR-24-03; LSU-24-089). ARRIVE checklist completed. Consent for publication: NA. Competing interests: ALB was an external consultant for EPL charged to design and manage the research for this study as a third-party contractor due to her publishing and science background in regenerative medicine. She is not an employee and had no equity or other arrangement to benefit from any data outcome.

References

This article includes 66 references
  1. Mock C, Cherian MN. The global burden of musculoskeletal injuries challenges and solutions.. Clin Orthop Relat Res 2008.
    pmc: PMC2584305pubmed: 18679760doi: 10.1007/s11999-008-0416-zgoogle scholar: lookup
  2. Fraile AP, González-Cubero E, Martínez-Flórez S, Olivera ER, Villar-Suárez V. Regenerative medicine applied to musculoskeletal diseases in equines: a systematic review.. Vet Sci 2023.
    pmc: PMC10748126pubmed: 38133217doi: 10.3390/vetsci10120666google scholar: lookup
  3. Horvath S, Singh K, Raj K, Khairnar S, Sanghavi A, Shrivastava A. Reversal of biological age in multiple rat organs by young porcine plasma fraction.. GeroScience 2024;46(1):367–94.
    pmc: PMC10828479pubmed: 37875652doi: 10.1007/s11357-023-00980-6google scholar: lookup
  4. Crawford KL, Ahern BJ. Investigations into thoroughbred racehorse welfare in Queensland Australia focused on musculoskeletal injuries and retirement.. Anim Front 2022;2(3):59–62.
    pmc: PMC9197301pubmed: 35711502doi: 10.1093/af/vfac018google scholar: lookup
  5. Legg KA, Gee EK, Breheny M, Gibson MJ, Rogers CW. Bioeconomic model for the thoroughbred racing industry—optimisation of the production cycle with a horse centric welfare perspective.. Animals 2023;13(3):479.
    pmc: PMC9913657pubmed: 36766368doi: 10.3390/ani13030479google scholar: lookup
  6. Bertoni L, Jacquet-Guibon S, Branly T, Legendre F, Desancé M, Mespoulhes C. An experimentally induced osteoarthritis model in horses performed on both metacarpophalangeal and metatarsophalangeal joints: technical, clinical, imaging, biochemical, macroscopic and microscopic characterization.. PLoS ONE 2020;15(6):e0235251.
  7. Tranquille CA, Chojnacka K, Murray RC. Musculoskeletal injury and illness patterns in British eventing horses: a descriptive study.. Animals 2024;14(18):2667.
    pmc: PMC11429326pubmed: 39335262doi: 10.3390/ani14182667google scholar: lookup
  8. Sutton JS, Muran A, Zaslav K, Grande D. Orthobiologics: an updated definition.. Open J Regen Med 2023;12(2):36–48.
    doi: 10.4236/ojrm.2023.122003google scholar: lookup
  9. Aratikatla A, Maffulli N, Rodriguez HC, Gupta M, Potty AG, El-Amin SF 3rd. Allogenic perinatal tissue for musculoskeletal regenerative medicine applications: a systematic review protocol.. J Orthop Surg Res 2022;17(1):307.
    pmc: PMC9188718pubmed: 35690774doi: 10.1186/s13018-022-03197-zgoogle scholar: lookup
  10. Zhang Z, Schon L. The current status of clinical trials on biologics for cartilage repair and osteoarthritis treatment: an analysis of ClinicalTrials.gov Data.. Cartilage 2022;13(2):19.
    pmc: PMC9152205pubmed: 35546280doi: 10.1177/19476035221093065google scholar: lookup
  11. O’Brien TJ, Hollinshead F, Goodrich LR. Extracellular vesicles in the treatment and prevention of osteoarthritis: can horses help us translate this therapy to humans?. Extracell Vesicles Circ Nucl Acids 2023;4:151–69.
    pmc: PMC10568983pubmed: 37829144doi: 10.20517/evcna.2023.11google scholar: lookup
  12. Bertone AL, Ishihara A, Zekas LJ, Wellman ML, Lewis KB, Schwarze RA. Evaluation of a single intra-articular injection of autologous protein solution for treatment of osteoarthritis in horses.. Am J Vet Res 2014;75(2):141–51.
    pubmed: 24471750doi: 10.2460/ajvr.75.2.141google scholar: lookup
  13. Muir SM, Reisbig N, Baria M, Kaeding C, Bertone AL. The concentration of plasma provides additional bioactive proteins in platelet and autologous protein solutions.. Am J Sports Med 2019;47(8):1955–63.
    pubmed: 31125271doi: 10.1177/0363546519849671google scholar: lookup
  14. Chen X, Jones IA, Park C, Vangsness CT Jr. The efficacy of platelet-rich plasma on tendon and ligament healing: a systematic review and meta-analysis with bias assessment.. Am J Sports Med 2018;46(8):2020–32.
    pmc: PMC6339617pubmed: 29268037doi: 10.1177/0363546517743746google scholar: lookup
  15. Lana JFSD, da Fonseca LF, Macedo RDR, Mosaner T, Murrell W, Kumar A. Platelet-rich plasma bone marrow aspirate concentrate: an overview of mechanisms of action and orthobiologic synergistic effects.. World J Stem Cells 2021;13(2):155–67.
    pmc: PMC7933989pubmed: 33708344doi: 10.4252/wjsc.v13.i2.155google scholar: lookup
  16. Reis IL, Lopes B, Sousa P, Sousa AC, Caseiro AR, Mendonça CM. Equine musculoskeletal pathologies: clinical approaches and therapeutical perspectives—a review.. Vet Sci 2024;11(5):190.
    pmc: PMC11126110pubmed: 38787162doi: 10.3390/vetsci11050190google scholar: lookup
  17. Baldwin P, Li DJ, Auston DA, Mir HS, Yoon RS, Koval KJ. Autograft, allograft, and bone graft substitutes: clinical evidence and indications for use in the setting of orthopaedic trauma surgery.. J Orthop Trauma 2019;33(4):203–13.
    pubmed: 30633080doi: 10.1097/bot.0000000000001420google scholar: lookup
  18. Bitar AC, Santos LA, Croci AT, Pereira JA, França Bisneto EN, Giovani AM. Histological study of fresh versus frozen semitendinous muscle tendon allografts.. Clinics (Sao Paulo) 2010;65(3):297–303.
  19. Carsi B, Lopez-Lacomba JL, Sanz J, Marco F, Lopez-Duran L. Cryoprotectant permeation through human articular cartilage.. Osteoarthritis Cartilage 2004;12(10):787–92.
    pubmed: 15450528doi: 10.1016/j.joca.2004.06.013google scholar: lookup
  20. Budaev AA, Borovkoval NV, Fain AM, Makarov MS, Storozheva MV, Andreev YV. Selection of an optimal cryoprotectant for long-term storage of human tendon allografts.. Transplantology 2022;14:312–21.
  21. Solanki K, Shanmugasundaram S, Shetty N, Kim SJ. Articular cartilage repair & joint preservation: a review of the current status of biological approach.. J Clin Orthop Trauma 2021;22:101602.
    pmc: PMC8488240pubmed: 34631411doi: 10.1016/j.jcot.2021.101602google scholar: lookup
  22. Dave U, Villarreal-Espinosa JB, Shah H, Cotter EJ, Gómez-Verdejo F, Carpenter M. Patients have similar clinical outcomes and failure rates after anterior cruciate ligament reconstruction with tibialis anterior tendon, bone-patellar tendon-bone, hamstring tendon, or achilles tendon allografts: a systematic review.. Arthrosc Sports Med Rehabil 2024;7(2):101035I.
  23. Wosicka-Frąckowiak H, Poniedziałek K, Woźny S, Kuprianowicz M, Nyga M, Jadach B. Collagen and its derivatives serving biomedical purposes: a review.. Polymers 2024;16(18):2668.
    pmc: PMC11435467pubmed: 39339133doi: 10.3390/polym16182668google scholar: lookup
  24. Frantz C, Stewart KM, Weaver VM. The extracellular matrix at a glance.. J Cell Sci 2010;123(Pt 24):4195–200.
    pmc: PMC2995612pubmed: 21123617doi: 10.1242/jcs.023820google scholar: lookup
  25. Aratikatla A, Maffulli N, Gupta M, Potti IA, Potty AG, Gupta A. Wharton’s jelly and osteoarthritis of the knee.. Br Med Bull 2024;149(1):13–31.
    pmc: PMC10993459pubmed: 38061765doi: 10.1093/bmb/ldad030google scholar: lookup
  26. Gupta A, Maffulli N. Allogenic umbilical cord tissue for treatment of knee osteoarthritis.. Sports Med Arthrosc Rev 2022;30(3):162–5.
    pubmed: 35921598doi: 10.1097/jsa.0000000000000350google scholar: lookup
  27. Bertone AL, Reisbig NA, Kilborne AH, Kaido M, Salmanzadeh N, Lovasz R. Equine dental pulp connective tissue particles reduced lameness in horses in a controlled clinical trial.. Front Vet Sci 2017;4:31.
    pmc: PMC5344919pubmed: 28344975doi: 10.3389/fvets.2017.00031google scholar: lookup
  28. Lowe J, Clifford L, Julian A, Koene M. Histologic and cytologic changes in normal equine joints after injection with 2.5% injectable polyacrylamide hydrogel reveal low-level macrophage-driven foreign body response.. J Am Vet Med Assoc 2024;262(5):649-647.
    pubmed: 38382205doi: 10.2460/javma.23.10.0553google scholar: lookup
  29. Christensen L, Camitz L, Illigen KE, Hansen M, Sarvaa R, Conaghan PG. Synovial incorporation of polyacrylamide hydrogel after injection into normal and osteoarthritic animal joints.. Osteoarthritis Cartilage 2016;24(11):1999–2002.
    pubmed: 27485850doi: 10.1016/j.joca.2016.07.007google scholar: lookup
  30. Tnibar A, Persson A, Jensen HE. Mechanisms of action of an intraarticular 2.5% polyacrylamide hydrogel (arthramid vet) in a goat model of osteoarthritis: preliminary observations.. J Biomed Eng 2017;3:1022–8.
  31. Pigott JH, Ishihara A, Wellman ML, Russell DS, Bertone AL. Investigation of the immune response to autologous, allogeneic, and xenogeneic mesenchymal stem cells after intra-articular injection in horses.. Vet Immunol Immunopathol 2013;156(1–2):99–106.
    pubmed: 24094688doi: 10.1016/j.vetimm.2013.09.003google scholar: lookup
  32. Sultan AA, Piuzzi NS, Mont MA. Nonoperative applications of placental tissue matrix in orthopaedic sports injuries: a review of literature.. Clin J Sport Med 2020;30(4):383–9.
    pubmed: 30365472doi: 10.1097/jsm.0000000000000684google scholar: lookup
  33. McIntyre JA, Jones IA, Danilkovich A, Vangsness CT Jr. The placenta: applications in orthopaedic sports medicine.. Am J Sports Med 2018;46:234–47.
    pubmed: 28375638doi: 10.1177/0363546517697682google scholar: lookup
  34. Wolkowski DD, McCarthy RD, Schoonover MJ, Taylor JD, Eastman TG. Effects of intra-articular injection of an acellular equine liquid amniotic allograft in healthy equine joints.. Vet Surg 2023;52(1):62–8.
    pubmed: 36408850doi: 10.1111/vsu.13918google scholar: lookup
  35. Southworth TM, Naveen NB, Nwachukwu BU, Cole BJ, Frank RM. Orthobiologics for focal articular cartilage defects.. Clin Sports Med 2019;38(1):109–22.
    pubmed: 30466717doi: 10.1016/j.csm.2018.09.001google scholar: lookup
  36. Wang KC, Frank RM, Cotter EJ, Christian DR, Cole BJ. Arthroscopic management of isolated tibial plateau defect with microfracture and micronized allogeneic cartilage-platelet-rich plasma adjunct.. Arthrosc Tech 2017;6(5):e1613–8.
    pmc: PMC5793087pubmed: 29399444doi: 10.1016/j.eats.2017.06.018google scholar: lookup
  37. Gupta A, El-Amin SF 3rd, Levy HJ, Sze-Tu R, Ibim SE, Maffulli N. Umbilical cord-derived Wharton’s jelly for regenerative medicine applications.. J Orthop Surg Res 2020;15(1):49.
    pmc: PMC7017504pubmed: 32054483doi: 10.1186/s13018-020-1553-7google scholar: lookup
  38. Lai A, Tamea C, Shou J, Okafor A, Sparks J, Dodd R. Retrospective evaluation of cryopreserved human umbilical cord tissue allografts in the supplementation of cartilage defects associated with hip osteoarthritis.. J Clin Med 2024.
    pmc: PMC11277460pubmed: 39064079doi: 10.3390/jcm13144040google scholar: lookup
  39. Penner M, Younger A, Wing K, Cresswell M, Veljkovic A. Arthroscopic repair of talar osteochondral defects with umbilical cord allograft: a prospective, single-center, pilot study.. Foot Ankle Spec 2021;14(3):193–200.
    pubmed: 32172597doi: 10.1177/1938640020910953google scholar: lookup
  40. Gupta A, Maffulli N, Rodriguez HC, Lee CE, Levy HJ, El-Amin SF 3rd. Umbilical cord-derived Wharton’s jelly for treatment of knee osteoarthritis: study protocol for a non-randomized, open-label, multi-center trial.. J Orthop Surg Res 2021;16:143.
    pmc: PMC7890617pubmed: 33602286
  41. Aratikatla A, Sidhu J, Maffulli N, Gupta M, Potty AG, Gupta A. Allogenic umbilical cord tissue for rotator cuff injuries.. Sports Med Arthrosc Rev 2023;1(3):73–9.
    pubmed: 37976128doi: 10.1097/jsa.0000000000000369google scholar: lookup
  42. . Centers for Medicare and Medicaid Services. Local Coverage Determination (LCD) L39575 Amniotic and Placental Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound. Effective Date Oct 26, 2023.. .
  43. McClellan A, Paterson YZ, Paillot R, Guest DJ. Equine fetal, adult, and embryonic stem cell-derived tenocytes are all immune privileged but exhibit different immune suppressive properties in vitro.. Stem Cells Dev 2019;28(21):1413–23.
    pubmed: 31507234doi: 10.1089/scd.2019.0120google scholar: lookup
  44. . Regulation of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) - Small Entity Compliance Guide. Guidance for Industry November 2022 FDA-2022-D-0563 Issued by Center for Biologics Evaluation and Research.. .
  45. Liu H, Sadygov RG, Yates JR 3rd. A model for random sampling and estimation of relative protein abundance in shotgun proteomics.. Anal Chem 2004;76(14):4193–201.
    pubmed: 15253663doi: 10.1021/ac0498563google scholar: lookup
  46. Lavoie C, Do C, Baker Z, Trabold M, Han J, Thaker H. Human umbilical cord allograft associated with higher pediatric urethrocutaneous fistula repair success rates.. J Pediatr Urol 2024;20(4):692.e1-692.e6.
    pubmed: 38951046doi: 10.1016/j.jpurol.2024.06.013google scholar: lookup
  47. Menarim BC, Gillis KH, Oliver A, Ngo Y, Werre SR, Barrett SH. Macrophage activation in the synovium of healthy and osteoarthritic equine joints.. Front Vet Sci 2020;7:568756.
    pmc: PMC7726135pubmed: 33324696doi: 10.3389/fvets.2020.568756google scholar: lookup
  48. . AI Overview. Small collagens in repair and regeneration. Latest Search Date June 11,2025.. .
  49. Bragdon B, Bertone AL, Hardy J, Simmons EJ, Weisbrode SE. Use of an isolated joint model to detect early changes induced by intra-articular injection of paclitaxel-impregnated polymeric microspheres.. J Invest Surg 2001;14(3):169–82.
    pubmed: 11453182doi: 10.1080/089419301300343327google scholar: lookup
  50. . Internet Website: https://kiffik.com/ Revolutionizing diagnostics through the power of interstitial fluid (ISF). Latest Access June 11, 2025.. .
  51. Moss KL, Jiang Z, Dodson ME, Linardi RL, Haughan J, Gale AL. Sustained interleukin-10 transgene expression following intra-articular AAV5-IL-10 administration to horses.. Hum Gene Ther 2020;31(1–2):110–8.
    pmc: PMC7872004pubmed: 31773987doi: 10.1089/hum.2019.195google scholar: lookup
  52. Linardi RL, Dodson ME, Moss KL, King WJ, Ortved KF. The effect of autologous protein solution on the inflammatory cascade in stimulated equine chondrocytes.. Front Vet Sci 2019.
    pmc: PMC6414419pubmed: 30895181doi: 10.3389/fvets.2019.00064google scholar: lookup
  53. Arend WP. The balance between IL-1 and IL-1Ra in disease.. Cytokine Growth Factor Rev 2002;13(4–5):323–40.
    pubmed: 12220547doi: 10.1016/s1359-6101(02)00020-5google scholar: lookup
  54. Barot D, Usimaki A, Linardi RL, Arensberg CM, Ortved KF. Equine autologous blood-based products contain variable quantities of transforming growth factor-β1, interleukin-1 receptor antagonist, and α2-macroglobulin.. Am J Vet Res 2025;86(4):ajvr.24.11.0363.
    pubmed: 39892397doi: 10.2460/ajvr.24.11.0363google scholar: lookup
  55. Camargo Garbin L, Morris MJ. A comparative review of autologous conditioned serum and autologous protein solution for treatment of osteoarthritis in horses.. Front Vet Sci 2021;8:602978.
    pmc: PMC7933025pubmed: 33681323doi: 10.3389/fvets.2021.602978google scholar: lookup
  56. Dutra HT, de Oliveira E, Ferreira JA, Bastos Queiroz PJ, de Araújo EG, Gaston Brandstetter LR. Short-term effects of platelet- rich plasma on the synovial fluid of horses with induced synovitis.. Ciênc Rural 2025;55:5.
  57. Frisbie DD, Kawcak CE, Werpy NM, Park RD, McIlwraith CW. Clinical, biochemical, and histologic effects of intra-articular administration of autologous conditioned serum in horses with experimentally induced osteoarthritis.. Am J Vet Res 2007;68(3):290–6.
    pubmed: 17331019doi: 10.2460/ajvr.68.3.290google scholar: lookup
  58. . Plasma Protein.. .
  59. Nixon AJ, Grol MW, Lang HM, Ruan MZC, Stone A, Begum L. Disease-modifying osteoarthritis treatment with interleukin-1 receptor antagonist gene therapy in small and large animal models.. Arthritis Rheumatol 2018;70(11):1757–68.
    pubmed: 30044894doi: 10.1002/art.40668google scholar: lookup
  60. Domaniza M, Hluchy M, Cizkova D, Humenik F, Slovinska L, Hudakova N. Two amnion-derived mesenchymal stem-cells injections to osteoarthritic elbows in dogs-pilot study.. Animals (Basel) 2023;13(13):2195.
    pmc: PMC10339997pubmed: 37443993doi: 10.3390/ani13132195google scholar: lookup
  61. Malek S, Weng HY, Martinson SA, Rochat MC, Béraud R, Riley CB. Evaluation of serum MMP-2 and MMP-3, synovial fluid IL-8, MCP-1, and KC concentrations as biomarkers of stifle osteoarthritis associated with naturally occurring cranial cruciate ligament rupture in dogs.. PLoS ONE 2020;15(11):e0242614.
  62. Mullen AC, Wrana JL. TGF-β family signaling in embryonic and somatic stem-cell renewal and differentiation.. Cold Spring Harb Perspect Biol 2017;9(7):a022186.
    pmc: PMC5495062pubmed: 28108485doi: 10.1101/cshperspect.a022186google scholar: lookup
  63. Zeng Y, Fu BM. Angiogenesis and microvascular permeability.. Cold Spring Harb Perspect Med 2025;15(1):a041163.
  64. Bao P, Kodra A, Tomic-Canic M, Golinko MS, Ehrlich HP, Brem H. The role of vascular endothelial growth factor in wound healing.. J Surg Res 2009;153(2):347–58.
    pmc: PMC2728016pubmed: 19027922doi: 10.1016/j.jss.2008.04.023google scholar: lookup
  65. Johnston GCA, Wood KA, Jackson KV, Perkins NR, Zedler ST. Evaluation of the inflammatory response to two intra-articular hyaluronic acid formulations in normal equine joints.. J Vet Pharmacol Ther 2020;43(1):38–49.
    pubmed: 31660636doi: 10.1111/jvp.12818google scholar: lookup
  66. Bertoni L, Jacquet-Guibon S, Branly T, Desancé M, Legendre F, Melin M. Evaluation of allogeneic bone-marrow-derived and umbilical cord blood-derived mesenchymal stem cells to prevent the development of osteoarthritis in an equine model.. Int J Mol Sci 2021;22(5):2499.
    pmc: PMC7958841pubmed: 33801461doi: 10.3390/ijms22052499google scholar: lookup

Citations

This article has been cited 0 times.